Clinical Trial Update: A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating subcutaneous mircera versus no ESA therapy for anemia in patients with chronic kidney disease after kidney transplant; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 4 | Status: TERMINATED